These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
522 related articles for article (PubMed ID: 35849877)
1. Comparison of actionable events detected in cancer genomes by whole-genome sequencing, in silico whole-exome and mutation panels. Ramarao-Milne P; Kondrashova O; Patch AM; Nones K; Koufariotis LT; Newell F; Addala V; Lakis V; Holmes O; Leonard C; Wood S; Xu Q; Mukhopadhyay P; Naeini MM; Steinfort D; Williamson JP; Bint M; Pahoff C; Nguyen PT; Twaddell S; Arnold D; Grainge C; Basirzadeh F; Fielding D; Dalley AJ; Chittoory H; Simpson PT; Aoude LG; Bonazzi VF; Patel K; Barbour AP; Fennell DA; Robinson BW; Creaney J; Hollway G; Pearson JV; Waddell N ESMO Open; 2022 Aug; 7(4):100540. PubMed ID: 35849877 [TBL] [Abstract][Full Text] [Related]
2. Tumour mutational burden, microsatellite instability, and actionable alterations in metastatic colorectal cancer: Next-generation sequencing results of TRIBE2 study. Antoniotti C; Korn WM; Marmorino F; Rossini D; Lonardi S; Masi G; Randon G; Conca V; Boccaccino A; Tomasello G; Passardi A; Swensen J; Ugolini C; Oberley M; Tamburini E; Casagrande M; Domenyuk V; Fontanini G; Giordano M; Abraham J; Spetzler D; Falcone A; Lenz HJ; Cremolini C Eur J Cancer; 2021 Sep; 155():73-84. PubMed ID: 34365081 [TBL] [Abstract][Full Text] [Related]
3. Tumor mutational burden analysis of 2,000 Japanese cancer genomes using whole exome and targeted gene panel sequencing. Hatakeyama K; Nagashima T; Urakami K; Ohshima K; Serizawa M; Ohnami S; Shimoda Y; Ohnami S; Maruyama K; Naruoka A; Akiyama Y; Kusuhara M; Mochizuki T; Yamaguchi K Biomed Res; 2018; 39(3):159-167. PubMed ID: 29899191 [TBL] [Abstract][Full Text] [Related]
4. Comparison of commonly used solid tumor targeted gene sequencing panels for estimating tumor mutation burden shows analytical and prognostic concordance within the cancer genome atlas cohort. Bevins N; Sun S; Gaieb Z; Thorson JA; Murray SS J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32217764 [TBL] [Abstract][Full Text] [Related]
5. Comprehensive analysis of potential immunotherapy genomic biomarkers in 1000 Chinese patients with cancer. Zang YS; Dai C; Xu X; Cai X; Wang G; Wei J; Wu A; Sun W; Jiao S; Xu Q Cancer Med; 2019 Aug; 8(10):4699-4708. PubMed ID: 31270941 [TBL] [Abstract][Full Text] [Related]
6. Paired analysis of tumor mutation burden calculated by targeted deep sequencing panel and whole exome sequencing in non-small cell lung cancer. Park S; Lee C; Ku BM; Kim M; Park WY; Kim NKD; Ahn MJ BMB Rep; 2021 Jul; 54(7):386-391. PubMed ID: 34154699 [TBL] [Abstract][Full Text] [Related]
7. Integrative Genomic Tests in Clinical Oncology. Imyanitov E; Sokolenko A Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361916 [TBL] [Abstract][Full Text] [Related]
8. Performance of Next-Generation Sequencing for the Detection of Microsatellite Instability in Colorectal Cancer With Deficient DNA Mismatch Repair. Ratovomanana T; Cohen R; Svrcek M; Renaud F; Cervera P; Siret A; Letourneur Q; Buhard O; Bourgoin P; Guillerm E; Dorard C; Nicolle R; Ayadi M; Touat M; Bielle F; Sanson M; Le Rouzic P; Buisine MP; Piessen G; Collura A; Fléjou JF; de Reyniès A; Coulet F; Ghiringhelli F; André T; Jonchère V; Duval A Gastroenterology; 2021 Sep; 161(3):814-826.e7. PubMed ID: 33992635 [TBL] [Abstract][Full Text] [Related]
9. Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non-Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel. Wang Z; Duan J; Cai S; Han M; Dong H; Zhao J; Zhu B; Wang S; Zhuo M; Sun J; Wang Q; Bai H; Han J; Tian Y; Lu J; Xu T; Zhao X; Wang G; Cao X; Li F; Wang D; Chen Y; Bai Y; Zhao J; Zhao Z; Zhang Y; Xiong L; He J; Gao S; Wang J JAMA Oncol; 2019 May; 5(5):696-702. PubMed ID: 30816954 [TBL] [Abstract][Full Text] [Related]
10. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach. Luchini C; Bibeau F; Ligtenberg MJL; Singh N; Nottegar A; Bosse T; Miller R; Riaz N; Douillard JY; Andre F; Scarpa A Ann Oncol; 2019 Aug; 30(8):1232-1243. PubMed ID: 31056702 [TBL] [Abstract][Full Text] [Related]
11. Use of an Integrated Pan-Cancer Oncology Enrichment Next-Generation Sequencing Assay to Measure Tumour Mutational Burden and Detect Clinically Actionable Variants. Pestinger V; Smith M; Sillo T; Findlay JM; Laes JF; Martin G; Middleton G; Taniere P; Beggs AD Mol Diagn Ther; 2020 Jun; 24(3):339-349. PubMed ID: 32306292 [TBL] [Abstract][Full Text] [Related]
12. Measurement of tumor mutational burden (TMB) in routine molecular diagnostics: in silico and real-life analysis of three larger gene panels. Endris V; Buchhalter I; Allgäuer M; Rempel E; Lier A; Volckmar AL; Kirchner M; von Winterfeld M; Leichsenring J; Neumann O; Penzel R; Weichert W; Glimm H; Fröhling S; Winter H; Herth F; Thomas M; Schirmacher P; Budczies J; Stenzinger A Int J Cancer; 2019 May; 144(9):2303-2312. PubMed ID: 30446996 [TBL] [Abstract][Full Text] [Related]
13. An Accurate and Comprehensive Clinical Sequencing Assay for Cancer Targeted and Immunotherapies. Cao J; Chen L; Li H; Chen H; Yao J; Mu S; Liu W; Zhang P; Cheng Y; Liu B; Hu Z; Chen D; Kang H; Hu J; Wang A; Wang W; Yao M; Chrin G; Wang X; Zhao W; Li L; Xu L; Guo W; Jia J; Chen J; Wang K; Li G; Shi W Oncologist; 2019 Dec; 24(12):e1294-e1302. PubMed ID: 31409745 [TBL] [Abstract][Full Text] [Related]
14. Benchmarking bioinformatics approaches for tumour mutational burden evaluation from a large cancer panel against whole-exome sequencing. Pang J; Xia H; Mi S; Zhang W; Pendrick D; Freeman C; Fernandes H; Mansukhani M; Hsiao SJ J Clin Pathol; 2023 Apr; 76(4):276-280. PubMed ID: 35906043 [TBL] [Abstract][Full Text] [Related]
15. Clinical Targeted Next-Generation sequencing Panels for Detection of Somatic Variants in Gliomas. Shin H; Sa JK; Bae JS; Koo H; Jin S; Cho HJ; Choi SW; Kyoung JM; Kim JY; Seo YJ; Joung JG; Kim NKD; Son DS; Chung J; Lee T; Kong DS; Choi JW; Seol HJ; Lee JI; Suh YL; Park WY; Nam DH Cancer Res Treat; 2020 Jan; 52(1):41-50. PubMed ID: 31096737 [TBL] [Abstract][Full Text] [Related]
16. Tumor Mutational Burden by Whole-Genome Sequencing in Resected NSCLC of Never Smokers. Ruel LJ; Li Z; Gaudreault N; Henry C; Saavedra Armero V; Boudreau DK; Zhang T; Landi MT; Labbé C; Couture C; Desmeules P; Joubert P; Bossé Y Cancer Epidemiol Biomarkers Prev; 2022 Dec; 31(12):2219-2227. PubMed ID: 36126278 [TBL] [Abstract][Full Text] [Related]
17. Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors. Cristescu R; Aurora-Garg D; Albright A; Xu L; Liu XQ; Loboda A; Lang L; Jin F; Rubin EH; Snyder A; Lunceford J J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35101941 [TBL] [Abstract][Full Text] [Related]
18. Assessments of tumor mutational burden estimation by targeted panel sequencing: A comprehensive simulation analysis. Li D; Wang D; Johann DJ; Hong H; Xu J Exp Biol Med (Maywood); 2023 Nov; 248(21):1918-1926. PubMed ID: 38062992 [TBL] [Abstract][Full Text] [Related]
19. Single-nucleotide variants, tumour mutational burden and microsatellite instability in patients with metastatic colorectal cancer: Next-generation sequencing results of the FIRE-3 trial. Stahler A; Stintzing S; von Einem JC; Westphalen CB; Heinrich K; Krämer N; Michl M; Modest DP; von Weikersthal LF; Decker T; Kiani A; Heintges T; Kahl C; Kullmann F; Scheithauer W; Moehler M; Kaiser F; Kirchner T; Jung A; Heinemann V Eur J Cancer; 2020 Sep; 137():250-259. PubMed ID: 32810748 [TBL] [Abstract][Full Text] [Related]
20. Tumor Mutation Burden as a Cornerstone in Precision Oncology Landscapes: Effect of Panel Size and Uncertainty in Cutoffs. Budak B; Arga KY OMICS; 2024 Apr; 28(4):193-203. PubMed ID: 38657109 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]